Phathom (PHAT) news

Recent news

Phathom Pharmaceuticals - topline results from Phase 2 trial expected in Q4 2026

AInvest Wire · Jun 23, 2026

Phathom shares paused for volatility

Phathom shares paused for volatility Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal disease treatments, saw its stock price experience a slight dip of 0.25% on June 6, 2025, trading at $4.70. This volatility is part of the broader market…

AInvest Wire · Jun 6, 2025

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by